HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)

Market Cap	285.10B
Revenue (ttm)	61.23B
Net Income (ttm)	-5.07B
Shares Out	83.98M
EPS (ttm)	-60.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	485,178
Average Volume	298,497
Open	3,315.00
Previous Close	3,325.00
Day's Range	3,310.00 - 3,510.00
52-Week Range	2,885.00 - 13,619.03
Beta	-0.88
RSI	58.84
Earnings Date	Nov 14, 2025

About HLB Therapeutics

HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers. The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 49
• Stock Exchange: KOSDAQ
• Ticker Symbol: 115450

Financial Performance

In 2024, HLB Therapeutics's revenue was 54.93 billion, an increase of 4.45% compared to the previous year's 52.59 billion. Losses were -22.79 billion, 890.1% more than in 2023.